atepeq/tico19 huggingface dataset:
These generally constitute tests designed to determine the major toxicities of a novel compound prior to first use in humans.
እዚ ጥቕልል ብዝበለ እቲ ናይ ኖቨል ውህድ ቅድሚ ኣብ ደቂ ሰባት ምሙካሩ ክህልዎ ዝኸእል ዓበዪ ናይ መርዛማነት ባህሪ ንምፍላጥ ዝዓለሙ ፈተነታት ዝሓዘ እዩ።
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, with plans to establish a "vaccine bank" of new vaccines for implementation if another coronavirus outbreak occurs.
ንCOVID-19 መድሓኒት ንምምዕባል ንዝሰርሑ 96 ናይ መጽናዕቲ ፕሮጀክታት ዝኸዉን CA$275 ሚልዮን መንግስቲ ካናዳ ኣበርኪቱ። ብተወሳኺ ናይ ካናዳ ዩኒቨርስትታት ናይ ክትባት ባንኪ ብምኽፋት ኣብ ቀፃሊ ንዘጋጥም ናይ ኮሮና ቫይረስ ለበዳ ንኽጠቅም ዝዓለመ ስራሕ ይሰርሑ ኣለዉ።
Clinical trial programs involve three, multiple-year stages toward product approval, and a fourth, post-approval stage for ongoing safety monitoring of the vaccine or drug therapy:
ክሊኒካል ናይ ፈተነ ፕሮግራም ሰለስተ፣ ናይ ብዙሓት-ዓመታት ደረጃታት ናይ ምህርቲ ፍቓድ ንምርካብ፣ ራብዓይ ድማ፣ ድሕሪ ፈቓድ ዘሎ ደረጃ ንናይ እቲ ክትባት ወይ መድሓኒት ደሕንነት ምቁጽጻር:
Phase I trials, usually in healthy volunteers, determine safety and dosing.
ፌዝ I ፈተነታት፣ መብዛሕትኡ ግዘ ኣብ ጥዕንኦም ዝተሓለወ ገበርቲ ሰናያት፣ ደሕንነትን ዶዚንግን ይውሰን።
Phase II trials are used to establish an initial reading of efficacy and further explore safety in small numbers of people having the disease targeted by the NCE.
ፌዝ II ፈተነታት ናይ መጀመርያ ናይ ምንባብ ብቕዓትን ተወሰኺ ናይ ዳህሰሳ ደሕንነትን ኣብ ኣናእሽተይ በዝሒ ዘለዎም እቲ ሕማም ዘለዎም ሰባት ብ NCE ኣብ ዒላማ ዘለዉ የካትት።
Phase III trials are large, pivotal trials to determine safety and efficacy in sufficiently large numbers of people with the COVID-19 infection.
መድረኽ III ፈተነታት ዓበይቲን፡ ድሕነትን ኣድማዕነትን ንምውሳን ኣብ ብዙሓት ብኮቪድ-19 ዝሓመሙ ሰባት ዝትግበሩ ወሰንቲ ፈተነታት እዮም።
If safety and efficacy are adequately proved, clinical testing may stop at this step and the NCE advances to the new drug application (NDA) stage to begin marketing.
ውሕስነት ከምኡውን ብእኹል ኩነታት እንተተረጋጊጾም ክሊኒካል መርመሪ ኣብ እዚ ደረጃ ክቋረጽ ይኽእል፡ ከምኡውን NCE ናብ ሓድሽ መድሕኒታት ምጥቃም(NDA) ደረጃ ብምስግጋር ናብ ዕዳጋ ምዝርጋሕ ክጅምር ይኽእል።
Phase IV trials are post-approval trials that may be a condition attached by the FDA, also called post-market surveillance studies.
ደረጃ IV ፈተነታት ብFDA ዝተትሓሓዘ ኮይኑ ድሕሪ ምፅዳቕ እቲ ፈተነ ዝካየድ ፖስት ማርኬት ናይ ክትትል መፅናዕቲ ተባሂሉ ዝፅዋዕ እዩ።
In addition to the tests required to move a novel vaccine or antiviral drug into the clinic for the first time, manufacturers must ensure that any long-term or chronic toxicities are well-defined, including effects on systems not previously monitored (fertility, reproduction, immune system, among others).
ን ኖቨል ክትባትውይድማ ናይ ፀረ ቫይረስ መድሓኒት ናብ ክሊኒክ ንመጀምሪያ ጊዜ ካብ ምምፃእ በትወሳኺ፣ መፍረይቲ ዝኾኑ ዓይነት ናይ ነዊ ሕ ጊዜ ውይድማ ሕዱር መርዛማነታት ብዝግባእ ክዝርዘሩን ክግለፁን ይግባእ፣ ን ኣብ ቅድም ኢሎም ኣብ ክትትል ዘይነበሩ ስርዓታት (ናይ ምፍራይ ተኽ እሎ፣ ምርባሕ፣ ናይ ሰብነት ሕማም ናይ ምክልኻል ዓቕሚ) ዝህልዎ ፅልዋ ሓዊሱ።
In the United States, this process is called a "new drug application" or NDA.
ኣብ ዩናይትድ ስቴትስ እዚ ከይዲ"new drug application" ወይ ድማ NDA ተባሂሉ ይፅዋዕ።
A clinical trial design in progress may be modified as an "adaptive design" if accumulating data in the trial provide early insights about positive or negative efficacy of the treatment.
ኣብ ከይዲ ዝርከብ ክሊኒካዊ ናይ ፈተነ ዲዛይን ኣብ ዳታ ምእካብ እዋን ቅድም ኢሉ ብዛዕባ ኣወንታዊን ኣሉታውን ውፅኢት ናይ እቲ መድሓኒት ግንዛበ ዝህበና እንተኾይኑ ከም "adaptive design"(ምስ ነገራት ዝለማመድ ንድፊ) ክሕደስ ይኽእል እዩ።
The global Solidarity and European Discovery trials of hospitalized people with severe COVID-19 infection apply adaptive design to rapidly alter trial parameters as results from the four experimental therapeutic strategies emerge.
ዓለምለኻዊ ሕብረትን ናይ ኣውሮፓ ናይ ኣብ ሆስፒታል ዝደቀሱ ከቢድ ናይ ኮቪድ-19 ረኽሲ ኣብ ዘለዎም ሰባት ዝግበሩ ፈተነታትን ካብቶም ዝወጹ ኣረባዕተ ናይ ፈተነ መድሓኒታት ሜላ ብቕልጡፍ ናይ ፈተነታት ኣካይዳ ንምቕያር እውን ዝተለመ እዩ።
Adaptive designs within ongoing Phase II-III clinical trials on candidate therapeutics may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, and coordinating design changes for a specific trial across its international locations.
ኣብ እቶም ኣብ ሕጹያት ሕክምናታት ቀጻሊ ዝግበሩ ዘለዉ ፈተነታት ደረጃ II-III ውሽጢ ዝርከቡ Adaptive designs(ምስ ነገራት ዝለማማዱ ንድፍታት) ናይ ምኮራ ጻንሒታት ከሕጹሩን ዝወሓዱ ኣርእስቲ ጉዳያት ክጥቀሙ ዝኽእሉ ብምዃኖም ኣቐዲምካ ንዝወሃቡ ናይ ምቁራጽን ዓወትን ውሳነታት ብምቅልጣፍ, ኣብ መላእ ዓለምለ ኣብ ዝርከቡ ቦታት ንዝህልዉ ውሱናት ሙከራታት ናይ ንድፊ ለውጢታት ከተሕሓባብሩ እውን ይኽእሉ እዮም።
Most novel drug candidates (NCEs) fail during drug development, either because they have unacceptable toxicity or because they simply do not prove efficacy on the targeted disease, as shown in Phase II-III clinical trials.
ደረጃ II-III ክሊኒካዊ ፈተነታት ከምዘርአ መብዛሕቲኦም ሓደሽቲ ናይ መድሃኒት ሕፁያት (NCEs) ኣብ እዋን ምዕባለ ይወድቁ። እቲ ምኽኒያት ድማ ዘየድሊ መርዛምነት ስለዘለዎም ወይ ድማ ኣብቲ ዝተተለመ ሕማም ዉፅኢታውነት እንተዘየርኢዩ እዩ።
The high failure rates associated with pharmaceutical development are referred to as an "attrition rate", requiring decisions during the early stages of drug development to "kill" projects early to avoid costly failures.
ምስ ፋርማሱቲካል ምዕባለ ዝተተሓሓዘ ልዑል ናይ ውድቀት ንጽጽር ቁጽሪ ናይ "ናይ ምድኻም ንጽጽር ቁጽሪ( attrition rate)" ተባሂሎም ዝጽውዑ እዮም፣ ኣብቲ ናይ መጀመርያ መድሓኒት ምዕባለ ደራጃታት ዋጋ ዘኽፍሉ ውድቀታት ንከየጋጥሙ ኣቐዲምካ ፕሮጀክትታት "ምቕታል" ዝብሉ ውሳነታት ኣድላይቲ እዮም።
One 2010 study assessed both capitalized and out-of-pocket costs for bringing a single new drug to market as about US$1.8 billion and $870 million, respectively.
ብመሰረት ሓደ ናይ 2010 ጽንዓት ዳህሰሳ፣ ሓንቲ ሓዳሽ መድሓኒት ናብ ዕዳጋ ንምጽንባር፣ ብመንገዲ ካፒታል $1.8 ቢልዮን፣ ካብ ጇባ ብዝወጽእ ድማ $870 ሚልዮን ዝኸውን ዋጋ ይሓትት።
A median cost estimate of 2015-16 trials for development of 10 anti-cancer drugs was $648 million.
ኣብ 2015-16 ንናይ ጸረ ካንሰር 10 መድሓኒታት ንምምዕባል ኣብ ዝተገበረ ፈተነ ዝወጸ ማእኸላይ ወጻኢ $648 ሚልዮን እዩ።
In a 2016 review of 106 drug candidates assessed through clinical trials, the total capital expenditure for a manufacturer having a drug approved through successful Phase III trials was $2.6 billion (in 2013 dollars), an amount increasing at an annual rate of 8.5%.
ኣብ ናይ 2016 ዝተገብረ መጽናዕቲ 106 ሕጹያት መድሕሓኒታት ብክሊኒካል ፈተነታት ተመርሚሮም፥ IIIፌዝ(ደረጃ) ፈተነታት መድሓኒት ንዘስርሕ ኣፍራይ ኣጠቓላሊ ወጻኢታቱ 2.6 ቢልዮን ዶላር (ብ2013) ኔሩ, እዚ ዓቐን ዓመታዊ ናብ 8.5% ይውስኽ ኣሎ።
Seven trials were evaluating repurposed drugs already approved to treat malaria, including four studies on hydroxychloroquine or chloroquine phosphate.
ሸውዓተ መጽናዕትታት ኣብ ንዓሶ ዝፍውሱ ዝነበሩ እሞ ዳግማይ ኣብ ዕላማ ንዝወዓሉ መድሃኒታት ይግምግሙ ኔሮም ።ኣርባዕተ መጽናዕትታት ድማ ኣብ ሃይድሮክሲክሎሮኪን ወይ ኣብ ክሎሮኪን ፎስፌት።
Repurposed antiviral drugs make up most of the Chinese research, with 9 Phase III trials on remdesivir across several countries due to report by the end of April.
ዳግማይ ኣብ ዕላማ ዝውዕሉ ዘለዉ ጸረ-ቫይረስ መድሃኒታት ኣብ መብዛሕትኡ መጽናዕትታት ቻይና ቦታ ሒዞም ይርከቡ፡፡ ብሰንኪ ድሕሪ ኣብ መወዳእታ ኣፕሪል ዝወጽአ ጸብጻብ ኣብ ብዙሓት ሃገራት ምስ 9 ኣብ ፌዝ III ናይ ፈተነ ግዜ ኣብ ረመድስቪር ዝካየድ መጽናዕቲ ይርከብ ።
Led by the Bill and Melinda Gates Foundation with partners investing US$125 million and coordinating with the World Health Organization, the COVID-19 Therapeutics Accelerator began in March, facilitating drug development researchers to rapidly identify, assess, develop, and scale up potential treatments.
ብ ድርጅት ቢልን መሊንዳን ጌትስ ተመሪሑ ምስ መሻርኽቲ ብምዃን 125 ሚልዮን ዶላር ኣሜሪካ ብምውፋርን ምስ ዓለማዊ ውድብ ጥዕና ብምትሕብባር ድማ ናይ COVID-19 ስነ-ፍወሳ መቀላጠፊ፡ መድሃኒት ናይ ምምዕባል መጽናዕትታት ብምጥጣሕ ንቅልጡፍ ምልላይ፡ ግምገማ፡ ምምዕባል ከምኡ’ውን ተኽእሎ ፍወሳ ንምዕባይ ኣብ መጋቢት ጀሚሩ።
The COVID-19 Clinical Research Coalition formed to coordinate and expedite results from international clinical trials on the most promising post-infection treatments.
ናይ COVID-19 ክሊኒካዊ መጽናዕቲ ዝተፈጠረ ጥምረት ንምቅንጃውን ንምቅልጣፍ ውጽኢት ምስ ዓለም ሓቛፊ ክሊኒካዊ ፈተነታት ብዛዕባ ካብ ረኽሲ ንድሓር ዝወሃብ ሕክምና ብጣዕሚ ተስፋ ወሃቢ እዩ።
In early 2020, numerous established antiviral compounds for treating other infections were being repurposed or developed in new clinical research efforts to alleviate the illness of COVID-19.
ኣብ መጀመርታ 2020 ንኻልኣኦት ሕማማት ንምፍዋስ ተባሂሎም ዝማዕበሉ ብዙሓት ጸረ-ቫይረስ ባእታታት፡ ንሕማም COVID-19 ንምቕላል ብጻዕርታት ሓደስቲ ክሊኒካዊ መጽናዕትታት ዳግማይ ከም ዝምዕብሉ ተገይሮም።
For an already-approved drug (such as hydroxychloroquine for malaria), Phase III-IV trials determine in hundreds to thousands of COVID-19-infected people the possible extended use of an already-approved drug for treating COVID-19 infection.
ፈቓድ ንዝረኸበ መድሓኒት (ከም hydroxychloroquine(ሃይድሮክሲክሎሮኲን) ንዓሶ)፣ ፌዝ III-IV ፈተነታት ናይ ኣማኢት ክሳብ ኣሽሓት ናይ ኮቪድ-19- ዝተተሓዙ ሰባት ዝተናወሐ ናይ ፈቓድ ዝረኸበ መድሓኒት ነዚ ኮቪድ-19 ረኽሲ ንምሕካም ምጥቃም ክውስን ይኽእል እዩ።
As of early April 2020, 103 candidate therapeutics were in preclinical or a stage of Phase I-IV development, with trial results for 29 drug candidates expected during April.
ካብ ሚያዝያ 2020 መጀመርያታት ጀሚሩ፣ 103 ሕጹያት መድሓታት ኣብ ቅድመ ክሊኒካል ፈተነ ወይ ኣብ መድረኽ I-IV ምዕባለ ደረጃ ነይሮም፣ ኣብ ሚያዝያ ትጽቢት ምስ ዝተገበሩ 29 ናይ መድሓታት ሕጹያት ድማ ውጽኢት ሂቡ።
In March, the World Health Organization (WHO) launched the coordinated "Solidarity trial" in 10 countries to rapidly assess in thousands of COVID-19 infected people the potential efficacy of existing antiviral and anti-inflammatory agents not yet evaluated specifically for COVID-19 illness.
ዓለማዊ ውድብ ጥዕና ኣብ መጋቢት ብዝተወሃሃደ ናይ “ስምረት ፈተነ” ንህሉው ኣድማዕነት፡ ብፍሉይ ኣንጻር ሕማም ኮቪድ-19 ዘይተገምገሙ ባእታታት ጸረ-ቫይረስን ጸረ-ነድርን ኣብ ኣሽሓት ብ ኮቪድ-19 ዝሓመሙ ሰባት ኣብ 10 ሃገራት ኣጀሚሩ ።
Do any of the drugs reduce mortality?
ገለ ካብዞም መድሓኒታት እዚኦም ሞተት ዝቕንሱ ድዮም?
Do any of the drugs reduce the time a patient is hospitalized?
ካብቶም ዝወሃቡ መድሓኒታት ናይ ሕሙማት ኣብ ሆስፒታል ዝፅንሑሉ ጊዜ ከሕጽሩ ዝኽእሉ ኣለው ዶ?
Do the treatments affect the need for people with COVID-19-induced pneumonia to be ventilated or maintained in intensive care?
እቶም ፍወሳታት ብሰንኪ ኮቪድ-19 ዝስዕብ ኒሞንያ ዝሓመሙ ሰባት ንፋስ ከም ዝረክቡ ክግበር ወይ ኣብ ጽዑቕ ክንክን ክጸንሑ ዘለዎም ኣድላይነት ይጸልው ድዩ?
Could such drugs be used to minimize the illness of COVID-19 infection in healthcare staff and people at high risk of developing severe illness?Enrolling people with COVID-19 infection is simplified by using data entries, including informed consent, on a WHO website.
ከምዚኦም ዝኣምሰሉ መድሓኒታት ኣብ ናይ ጥዕና ሰራሕተኛታትን ነቶም ኣብ ከቢድ ሕማም ናይ ምምዕባል ሓደጋ ውሽጢ ዘለዉ ሰባትን ዝህሉ ናይ COVID-19 ሕማም ንምቕናስ ይጠቅሙ ዶ ይኾኑ? ብ COVID-19 ዝተተሓዙ ሰባት ምምዝጋብ ኣብ ናይ WHO መርበብ ሓበሬታ ውሽጢ ዝርከብ informed consent(ሰብ ሞያ ጥዕና ን ሕሙማት ዝህብዎ ሓበሬታ) ሓዊሱ ዳታ ምእታው ብምጥቃም ቀሊሉ ኣሎ።
After the trial staff determines the drugs available at the hospital, the WHO website randomizes the hospitalized subject to one of the trial drugs or to the hospital standard of care for treating COVID-19.
ጉጅለ ኣባላት ፈተነ ኣብ ሆስፒታል ክህልው ዘለዎም መድሃኒታት ምስ ወሰነ መርበብ ሓበሬታ WHO ኣብ ሆስፒታል ንመጽናዕቲ ዝተዓቖቡ ሕሙማት ናብ ሓደ ካብቶም ናይ ፈተነ መድሃኒታት ወይ ናይ’ቲ ሆስፒታል ንቡር ፍወሳ ናይ COVID-19 ብሃውሪ ይምድብ ።
The trial physician records and submits follow-up information about the subject status and treatment, completing data input via the WHO Solidarity website.
ናብ ናይ WHO ምትሕግጋዝ መርበብ ሓበሬታ ዳታ ዝኣቱ ሓበሬታ መሊኦም ብምውዳእ ፈተነ ዶክተራት ዛዕባ ናይ ሕሙማት ኩነታትን ዝወሃቦም ዘሎ ሕክምናን፣ ዘሎ ናይ ክትትል ሓበሬታታት መዝጊቦም የረክብዎ እዮም።
A global safety monitoring board of WHO physicians examine interim results to assist decisions on safety and effectiveness of the trial drugs, and alter the trial design or recommend an effective therapy.
ናይ ዓለማዊ ውድብ ጥዕና ሓካይም ዝሓቖፈ ዓለማዊ ናይ ድሕነት ተቖጻጻሪ ቦርድ፡ ንምሕጋዝ ውሳነታት ኣብ ድሕነትን ኣድማዕነትን ናይ ፈተነ መድሃኒታት ከምኡ'ውን ንምቕያር ናይ ፈተነ ንድፊ ወይ ኣድማዒ ፍወሳ ንምምካር ክስዖይ ዝተረኽቡ ውጽኢታት ይምርምሩ።
A similar web-based study to Solidarity, called "Discovery", was initiated in March across seven countries by INSERM (Paris, France).During March, funding for the Solidarity trial reached US$108 million from 203,000 individuals, organizations and governments, with 45 countries involved in financing or trial management.
ብተመሳሳሊ ብ INSERM (ፓሪስ, ፈረንሳይ) ኣቢሉ "Discovery" ዝተብሃለ ኣብ መርበብ ዝተድረኸ ናይ ምትሕብባር መፅናዕቲ ኣብ ወርሒ መጋቢት ኣብ ውሽጢ ሸዋዓተ ሃገራት ክጅመር ተገይሩ ኣሎ። ኣብ ወርሒ መጋቢት ፣ኒቲ ናይ ምትሕብባር ሙከራ ዝግበር ሓገዝ ገንዘብ ካብ 203,000 ውልቀሰባት፣ትካላትን መንግስቲታትን፣ ምስ 45 ሃገራት ኣብ ፋይናንሳዊ ን ናይ ሙከራ ምሕደራን ኣብ ዝተሳተፋሉ ዝተኣከበ ገንዘብ US$108 ሚሊዮን ቢፂሑ እዩ።
Numerous candidate drugs under study as "supportive" treatments to relieve discomfort during illness, such as NSAIDs or bronchodilators, are not included in the table below.
ኣብ መጽናዕቲ ዝርከቡ ብዙሓት ሕጹያት መድሃኒታት ኣብ ግዜ ሕማም ቃንዛታት ንምንካይ ከም NSAID ወይ መድሃኒታት ስርዓተ ምስትንፋስ ከም “ድጋፍ ዝህቡ” ፍወሳታት ኣብ ታሕቲ ኣብ ሰሌዳ ኣይተዘርዘሩን ።
Others in early-stage Phase II trials or numerous treatment candidates in Phase I trials, are also excluded.
ካልኦት ኣብ መጀመርታ-ግዜ ናት ፌዝ II ፈተነ ዝርከቡ ወይ ኣብ ፌዝ I ዝርከቡ ንፍወሳ ዝተሓጽዩ ብዙሓት ሰባት ኣብ'ቲ መጽናዕቲ ካብ ምስታፍ ተፈልዮም ኔሮም።
Drug candidates in Phase I-II trials have a low rate of success (under 12%) to pass through all trial phases to gain eventual approval.
ኣብ ፌዝ I-II ፈተነታት ዘለዉ ናይ መድሓኒት ሕጹያት ብኩሎም ናይ ፈተነ ፌዛት ንክሓልፉን ፈቓድ ንክረኽቡ ትሑት ናይ ምዕዋት ተኽእሎ ኣለዎም (ትሕቲ 12%) ።
Hydroxychloroquine is more commonly available than chloroquine in the United States.
ኣብ ሕቡራት መንግስታት ኣሜሪካ ሃይድሮክሲክሎሮኪን ካብ ክሎሮኪን ዝያዳ ይርከብ ።
Although several countries use chloroquine or hydroxychloroquine for treatment of persons hospitalized with COVID-19, as of March 2020 the drug has not been formally approved through clinical trials in the United States.
ዋላ እኳ ብዙሓት ሃገራት ንክሎሮኪን ወይ ሃይድሮክሎሮኪን ብኮቪድ-19 ኣብ ሆስፒታል ንዝተዓቑቡ ሕሙማት ንምፍዋስ ይጥቀማሉ እንተኾና፡ ካብ ማርች 2020 ጀሚሩ እቲ መድሃኒት ኣብ ኣሜሪካ ብክሊኒካዊ ፈተነታት ተፈቲኑ ኣብ ተቐባልነት ኣይበጽሐን።
Chloroquine has been recommended by Chinese, South Korean and Italian health authorities for the treatment of COVID-19, although these agencies and the US CDC noted contraindications for people with heart disease or diabetes.
ክሎሮኪን ንፍወሳ COVID-19 ብ ቻይናውያን፡ ደቡብ ኮርያውያን ከምኡ’ውን ጣልያናውያን በዓል መዚ ጥዕና ምሕጽንታ ተገይሩሉ እዩ ።ነገር ግን እዘን ትካላትን ናይ ኣሜሪካ ማእከል ምቁጽጻር ሕምማትን ንናይ ልቢ ሕማም ወይ ሽኮርያ ዘለዎም ሰባት ተጓዳኢ ክኸውን ከም ዝኽእል’ውን ኣገንዚቦም።
Both drugs have extensive interactions with prescription drugs, affecting the therapeutic dose and disease mitigation.
ክልቲኦም መድሓኒታት ምስ ዝእዘዙ መድሓኒታት ኣዝዩ ጥቡቕ መስተጋብር ኣለዎም ኣብ ናይ ሕክምናዊ ዝወሰድ መጠኝን ናይ ሕማማ ናይ ምውቃዕ ዓቕሞም ድማ ፅልዋ የሕድሩ።
Some people have allergic reactions to these drugs.On 12 April, a preliminary clinical trial conducted at a hospital in Brazil was stopped when several people given high doses of chloroquine for COVID-19 infection developed irregular heart rates, causing 11 deaths.
ገለ ሰባት ነዞም መድሓኒታት ኣላርጂክ ዓጸፋዊ መልሲ ኣለዎም።ኣብ 12 ኣፕሪል፣ ኣብ ናይ ብራዚል ሆስፒታል ክካየድ ጀሚሩ ዝነበረ ፐሪሊሚናሪ ክሊኒካዊ ፈተነ ብዙሓት ሰባት ንኮቪድ-19 ልዑል ናይ chloroquine ዶዝ ድሕሪ ምውሃቦም ዘይስሩዕ ናይ ልቢ ውቅዒት ከማዕብሉ ብምኽኣሎምን 11 ሰባት ድማ ስለ ዝሞቱ ደው ክብል ተገይሩ እዩ።
Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective".
ኣብ ዉሃንን ሸንዥንን ዝርከብ ናይ ቻይና ክሊኒካዊ ፈተነ ፋቪፓቪር ‘’ብንፁር ዉፅኢታዊ’’ ምዃኑ ሓቢሮም።
Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
ካብቶም ኣብ ሸንጀን ኣብ ዉሽጢ 4 መዓልቲታት ካብቲ ቫይረስ ናፃ ዝተብሃሉ 35 ሰባት፣እቶም ዘይወሰዱ 45 ሰባት ድማ ን 11 መዓልቲታት ዝኾን ኣብ ሕማም ፀኒሖም እዮም።
In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir.
ኣብ ልዕሊ 240 ኒሞንያ ዘለዎም ሰባት ኣብ ዉሃን ዝተገብረ መጽናዕቲ፡ ፍርቆም ፋቪፒራቪር ኵአሃቡ ከለዉ ፍርቆም ድማ ኡሚፈኖቪር ተዋሂቦም።
The term "preclinical research" is defined by laboratory studies in vitro and in vivo, indicating a beginning stage for development of a vaccine, antiviral or monoclonal antibody therapy, such as experiments to determine effective doses and toxicity, before a candidate compound is advanced for safety and efficacy evaluation in humans.
“ቅድመ-ክሊኒካዊ መጽናዕቲ” ዝብል ቃል ንዝኾነ ሕጹይ መድሃኒት ብዝምልከት ናይ ድሕነትን ኣድማዕነትን ግምገማ ቅድሚ ምትግባሩ ከም ንመጠንን መርዛምነትን ንክውሰን ኣብ ውሽጢ ሰብነትን ወጻኢን ሙከራታት ብምትግባር ንምምዕባል ክታበት፡ ጸረ-ቫይረስ ወይ ሞኖክሎናል ኣንቲቦድዲ ፍወሳ ብምምልካት ዝግበር ናይ ጀማራይ ደረጃ ናይ ላቦራቶሪ መጽናዕቲ ተባሂሉ ይግለጽ ።
Some antibiotics may be repurposed as COVID-19 treatments:
ገለ ጸረ-ረኽሲ መድሓኒታት ከም ናይ ኮቪድ-19 መድሓኒታት ኮይኖም ደጊሞም ክቐርቡ ይኽእሉ እዮም:
In March 2020, the main protease of the SARS-CoV-2 virus was identified as a target for post-infection drugs.
ኣብ ማርች 2020፣ ናይ SARS-CoV-2 ቫይረስ ዋና ዕላማ ንናይ ድሕሪ ረኽሲ መድሓኒታት ዕላማ ዝገበሩ ተባሂሎም ተፈልዮም።
This enzyme is essential to the host cell to reproduce the ribonucleic acid of the virus.
ናይ እቲ ተሸካማይ ዋህዮ ራይቦኑክሊክ ኣሲድ ንምርባሕ እዚ ኤንዛይም ኣገዳሲ እዩ።
To find the enzyme, scientists used the genome published by Chinese researchers in January 2020 to isolate the main protease.
ነቲ ነፍሳዊ ቀመም ንምርካብ፡ ተመራመርቲ ስነ-ፍልጠት ብ ቻይናውያን ተመራመርቲ ኣብ ጃንዋሪ 2020 ዝተሓተመ ሕነት-ሰረት ነቲ ቀንዲ ናይ ፕሮቲን ነፍሳዊ ቀመም ንምፍላይ ተጠቂሞምሉ ።
As a potential combination therapy, they are used together in two Phase III arms of the 2020 global Solidarity project on COVID-19.
ከም ሓበራዊ ሕክምና፣ ኣብ ክልተ ፌዛት III ናይ 2020 ዓለምለኻዊ ናይ ጥንካረ ፕሮጀክት ናይ ኮቪድ-19 ብሓባር ኣብ ጥቕሚ ውዒሎም።
A preliminary study in China of combined lopinavir and ritonavir found no effect in people hospitalized for COVID-19.
ኣብ ሕዋስ ናይ ሎፒናቪርን ሪቶናቪርን ኣብ ቻይና ዝተገብረ መባእታዊ መጽናዕቲ ኣብ ብሰንኪ COVID-19 ሆስፒታል ዝኣተዉ ሰባት ውጽኢት ዘይብሉ ኮይኑ ተረኺቡ ።
b'Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed.
b'Drug ደጊምካ ምመሕያሽ (ናይ መድሓኒት ደጊምካ ንካልእ ዕላማ ምውዓል፣ ሪ -ፕሮፋይሊንግ፣ ንካልእ ስራሕ ምውዓል ወይ ናይ መድሓኒት ምቕያር እውን ተባሂሉ ይፍለጥ) ንካልእ ሕማም ወይ ናይ ጥዕና ኩነታት ክሕክም ኣፍልጦ ዝተወሃቦ መድሓኒት ንካሊእ ሕማም ክውዕል ምግባር ማለት እዩ።
This is one line of scientific research which is currently being pursued to develop safe and effective COVID-19 treatments.
እዚ ኣብ’ዚ ግዜ’ዚ ኣድማዕነቱን ድሕነቱ ዘተኣማምንን ናይ COVID-19 ፍወሳታት ንምምዕባል ክትትል ዝግበረሉ ሓደ መስመር ናይ ሳይንሳዊ መጽናዕቲ እዩ።
Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.SARS-CoV-2 has about 66 druggable proteins, each of which has multiple ligand binding sites.
ካልኦት ናይ መጽናዕቲ ኣንፈታት ናይ ኮቪድ -19 ክትባት ምምዕባልን ኮንቨልሰንት ፕላስማ ትራንስፊዩዢንን ዘካትት እዩ። SARS-CoV-2 66 ዝኾኑ መድሓኒት ክስርሖም ዝኽእሉ ፕሮቲናት ኣለዉ፣ ሕድሕዶም ብዙሓት ሊጋንድ መትሓዚ ቦታታት ኣለዎም።
Analyzing those binding sites provide the reasonable project of developing effective antiviral drug against COVID-19 proteins.
መላገቢ ቦታታት ምምርማር ኣንጻር COVID-19 ፕሮቲናት ኣድማዒ ዝኾነ መድሃኒት ንምምዕባል ሓቀኛ ዝኾነ ዕቅድ የቕርብ።
Of the most important SARS-CoV-2 target proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
ካብ ናይ SARS-CoV-2 ዕላማ ዝግበሩ ፕሮቲናት ኣዚዮም ጠቐምቲ ፓፓይን-ዓይነት ፕሮቴዝ፣ RNA ጽግዕተኛ RNA ፖሊመሬዝ፣ ሄሊኬዝ፣ S ፕሮቲንን ADP ራይቦፎስፊቴዝን እዮም።
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
Hussein AA, et al ዝተፈላለዩ ዉሁዳት ኣጽኒዑ ድሕሪኡ ድማ ምስቲ ልዑል ተመሳሳሊ ኣፍልጦ ዝተወሃቦ መድሓኒት ናይ ብቑዕ ጸረ -SARS-CoV-2 መድሓኒት ምዕባለ ኣብ ቅድመ ክሊኒካዊ መጽናዕቲ ኣብ ክሊኒካል መጽናዕቲ ንድፊ ክውስኽን ክገብር ድማ ክኢሉ።
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
ክሎሮክዊን ናይ ዓሶ መድሓኒት ኮይኑ ንሓደሓደ ኣዉቶኢምዩን ሕማማት እዉን ይጥቀም እዩ።
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
ብማርች 18 WHO ክሎሮኪንን ምስኡ ዝዛመድ ሃይድሮክሲክሎሮኪንን ካብቶም ኣርባዕተ ከም ኣካል ስምረት ክሊኒካዊ ፈተነታት ዝተጸንዑ መድሃኒታት ከምዝኾኑ ኣፍሊጡ።
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
ናይ ኒውዮርክ ኣማሓዳሪ ኣንድሪው ኩዎሞ ናይ ኒውዮርክ ግዝኣት ናይ chloroquine(ክሎሮኲን) ን hydroxychloroquine(ሃይድሮክስይልክሎሮኲን) ን ፈተነ ኣብ 24 ማርች ከምዝጅምር ሓቢሮም።ኣብ 28 ማርች፣ FDA ናይ hydroxychloroquine sulfate(ሃይድሮክስይልክሎሮኲን ሰልፌት)ን chloroquine phosphate(ክሎሮኲን ፎስፌት) ን ኣብ ትሕቲ ሃንደበታዊ ጥቕሚ ፈቓድ (EUA) ንምጥቃም ፈቓድ ሂቡ።
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
እቲ ፍወሳ ብ ክሊኒካዊ መጽናዕትታት ናይ FDA ተቐባልነት ዝረኸበ ኣይኮነን ከምኡ’ውን ብ ናይ EUA ህጹጽ እዋን ፍቓድ ኣብ ሆስፒታል ደቂሶም ኣብ ክሊኒካዊ ፈተነታት ግን ፍወሳ ክረኽቡ ንዘይከኣሉ ሕሙማት ከም ናይ ሙከራ ህጹጽ ፍወሳ እዩ ተፈቒዱ።
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
CDC ‘’ንSARS-CoV-2 ረኽሲ ሃይድሮክሲክሎሮክዊን ከም መከላኸሊ ወይድማ ከም መድሃኒት ክንጥቀመሉ ከምዝከኣል’’ ገና ኣይተሰረተን ኢሉ።
Doctors have said they are using the drug when "there's no other option".
ዶክተራት “ካልእ ኣማራጺ ምስ ዘይህልው” ነቲ መድሃኒት ከም ዝጥቀሙሉ ሓቢሮም ኣለዉ።
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
ኣብ ኢስታንቡል ናይ ቱርኪ ናይ መጽናዕቲ ጉጅለ ንእሽተይ ምጽናዕቲ ኣብ ኣጠቓቕማ ክሎሮኪን ምስ ዚንክ፡ ቫይታሚን ኤ፡ ቫይታሚን ሲ ከምኡ’ውን ቫይታሚን ዲ የካይድ ኣሎ ።
Large studies are underway at Duke University and the University of Oxford.
ኣብ ዱክ ዩኒቨርሲቲ ን ኣብ ኦክስፎርድ ዩኒቨርሲቲን ዓባይቲ መፅናዕቲታት እናትኻየዱ ይርክቡ።
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
NYU Langone ናይ ሕክምና ቤት ትምህርቲ ንናይ hydroxychloroquine ምክልኻል ኣጠቓቕማ ናይ ደሕንነትን ብቕዓትን ፈተነ የካይድ ኣሎ።
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
ናይ ቻይና ክሊኒካል ፈተነታት ኣብ ውሃንን ሺንዘንን favipiravir(ፋቪፒራቪር) "ብግልጺ ብቑዕ" ከምዝኾነ ኣርእዮም እዮም።
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
ኣብ ሸንጀን ኣብ ዉሽጢ 4 መዓልቲታት ካብቲ ቫይረስ ናፃ ዝተብሃሉ 35 ሰባት፣ እቶም ዘይወሰዱ 45 ሰባት ድማ ን 11 መዓልቲታት ዝኾን ኣብ ሕማም ፀኒሖም እዮም።
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
ኣብ ውሃን ኣብ 240 ናይ ሳንቡእ ውቕዒ ዘለዎም ሕሙማት ዝተገበረ መጽናዕቲ፣ ፍርቆም favipiravir ፍርቆም ድማ umifenovir ክዋሃቡ ተገይሩ እዩ።
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
ናይ ጣልያን ፋርማሲቲካዊ ትካል ነቲ መድሃኒት ዝድግፍ ህሉው መርትዖ መባእታዊን ዘይእኹልን ከም ዝኾነ ንህዝቢ ኣዘኻኺሩ።
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
ኣብ ማርች 2, ጀርመን ነቲ መድሃኒት ካብ ጃፓን ንምእካብ ከምእትገዝኦን ናብ ሕሙማት COVID-19 ዝሕከሙሉ ሆስፒታላት ዩኒቨርሲቲ ንምዝርጋሕ ሰራዊት ከም ትጥቀምን ኣፍሊጣ።
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
ብ መሰረት ናይ ደቡብ ቻይና ሞርኒንግ ፖስት( South China Morning Post) ከምዝበሎ፣ ሺንዞ ኣቤ ብዛዕባ እቲ መድሓኒት ምዕዳግ ንናይ ትራምፕ ምምሕዳር ኣቕርቦታት ከምዘቕረበ ሓቢሩ።እዚ መድሓኒታት ኣብ ከበድቲ ጉዳያት ለበዳ ክንድ'ቲ ዘይክጠቅም ይኽእል እዩ እቲ ቫይረስ ኣዝዩ ዝተባዛሐ ብምዃኑ።
It may not be safe for use by pregnant women or those trying to conceive.
ብ ጥኑሳት ውይድማ ጥንሲ ንምሓዝ ብዝምኩራ ዘለዋ ደቂ ኣንስትዮ ኣብ ጥቅሚ ምውዓሉ ውሑስ ዘይክኽውን ይኽእል።
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
ሓደ መጽናዕቲ ኣብ ሎፒናቪር/ሪቶናቪር(ካሌትራ) ዝተገብረ፡ ውህደት ናይ ጸረ-ቫይረስ መድሃኒታት ሎፒናቪርን ሪቶናቪርን ”ምንም ጥቕሚ ከምዘነበሮም” ደምዲሙ ኣሎ ።
The drugs were designed to inhibit HIV from replicating by binding to the protease.
እዞም መድሓኒታት HIV ምስ ፕሮቴዛት ብምትሕሓዝ ከይባዛሕ ዝኽእልክሉ እዮም።
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
ኣብ ኮሎራዶ ዩኒቨርሲቲ ዘለዉ ኣጽናዕቲ ጉጅለ ምስ ናይ SARS-CoV-2 ፕሮቴዝ ዝተሓሓዘ ኮምፓውንድ ንምፍጣር መድሓኒታት ከመሓይሹ ይፍትኑ ኣለዉ።ኣብ እቲ ናይ ሳይንሳዊ ማሕበረ ሰብ ን HIV/AIDS(ኤች ኣይ ቪ/ ኤዲስ) ጥራሕ ተባሂሎም ዝማዕበሉ መድሓኒታት ንካልእ ዓላማ ንምውዓል ሓፍቲታት ኣብጥቕሚ ይውዕሉ ኣለዉ ብዝብል ነቐፌታ ኣሎ።
The WHO included lopinavir/ritonavir in the international Solidarity trial.
ውድብ ጥዕና ዓለም(WHO) lopinavir/ritonavir(ሎፒናቪር/ሪቶናቪር) ኣብቲ ዓለምለኻዊ ናይ ምትሕግጋዝ ፈተነ ኣጠቓሊሎምዎ ኣለዉ።
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Remdesivir(ሬምድስቪር) ብ Gilead Sciences ን ናይ ኢቦላ ቫይረስ ሕማምን ማርበርግ ቫይረስ ረኽሲን ንክከላኸል ተፈጢሩ።Gilead Sciences እዚ Remdesivir(ሬምድስቪር) ኣንጻር ዝተፈላለዩ ፊሎ -፣ ኒሞ -፣ ማራሚክሶ -፣ከምኡውን ኮሮና- ቫይረሳት ናይ ጸረ ቫይረስ ንጥፈታት ከምዘለውዎ ጸኒሖም ተረዲኦሞ።
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
ናይ እዞም ጸረ-ቫይረስ መድሓኒታት ሓደ ጸገም ብሚቹዌሽን ናይ ምጽዋር ዓቕሚ ምምዕባል እዩ፣ እዚ ድማ ናብ ዝኸበደ ሕማምን ዝርጋሐን ከምርሕ ይኽእል እዩ።
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
ገለ ቅድም ክብሉ ዝወጹ ቅድመ ፈተነ መጽናዕቲታት remdesivir ንምጽዋር ልዑል ጀነቲክ ገደብ ኣለዎ ኢሎም።ብ ክሊቭላንድ ዩኒቨርሲቲ ሆስፒታላት ዝተኻየዱ ክልተ ፈተነታት፡ ሓደ ን ማእኸላይ ሕማም ዘለዎም ሰባት ሓደ ድማ ን ከቢድ ሕማም ዘለዎም ሓዊሱ ብዙሓት ክሊኒካዊ ፈተነታት ይካየዱ ኣለዉ እዮም።
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
ኣብ እዚ ሕዚ እዋን ብምኽንያት COVID-19 ከቢድ ሕማም ሒዝዎም ናብ ሕክምና ንዝኣተዉ ሕሙማት ብደም ሱር ዝወሃብ ቫይታሚን ሲ ዘፅንዑ ሰለስተ ክሊኒካዊ ፈተነታት ኣለዉ። ካብዚኦም ድማ፡ ክልተ ናይ ፕላሴቦ ቁፅፅር (ቻይና፣ካናዳ) ሓደ ድማ ብዘይ ቁፅፅር (ጣልያን) ኣለዎም።
New York State began trials for the antibiotic azithromycin on 24 March 2020.
ኣብ ማርች 24፣ 2020 ናይ ኔውዮርክ ክልል ናይ ኣዚትሮማሲን ዝተብሃለ ፀረ-ተሃዋስያን ሙከራ ጅሚራ ኣላ።
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
ጃፓን ብሄራዊ ናይ ዓለማዊ ጥዕናን ሕክምናን ማእኸል (NCGM) Teijin's Alvesco (ciclesonide) ተባሂሉ ዝፅዋዕ ንኣስሚ ዝጠቅም ዝትንፈስ ኮርቲኮስቴሮይድ ናይ ኖቭል ኮሮና ቫይረስ ምልክት ገና ንዘየርአዩ ሕሙማት ከም ፈዉሲ ዝጠቅም ምዃኑ ንምምርማር ናይ ክሊኒካዊ ፈተነ ከምዝጅምር ኣፍሊጡ።
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
ካብ ዴንማርክ፣ጀርመንን ኣዉስትሪያን ኣብ ሕክምና ዝርከቡ ከቢድ ሕማም ዘጋጠሞም 200 ሕሙማት ተወሲዶም ንዉፅኢታዉነት ናይ angiotensin-converting enzyme 2 ደረጃ II ፈተነ ኣብ መስርሕ ኣሎ።
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
ናይ ኣብ ካናዳ ዝርከብ Montreal ናይ ልቢ ትካል colchicine(ክሎኪሳይን) ኣብ ቀሊል ኮቪድ-19 ምልክታት ዘለዎም ሰባት ናይ ፑልሙናሪ ሕልኽላኻትን ቁጠዐን ኣብ ምቕናስ ዘለዎ ግደ ኣብ ምጽናዕ ይርከቡ።
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
እቲ COLCORONA ተባሂሉ ዝፅዋዕ መፅናዕቲ 6000 ዝኾኑ ዕድሜኦም ካብ 40 ንላዕሊ ዝኾኑ ብCOVID-19 ዝተትሓዙን ቀሊል ዝበሃል ምልክታት ዘርኣዩ፡ ሕክምና ዘየድልዮም ሕሙማት ኣብ ምምልማል ይርከብ።
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
ጥኑሳት ወይ ጸባ ጡብ ዝዕንግላ ኣዴታት ወይ ኣድማዒ ናይ ጥንሲ መከኸሊ ኣገባብ ዘብለን ብቑዓት ኣይኮናን።
Several anticoagulants are being tested in Italy.
ብዙሓት ጸረ-ምርጋእ ዝኾኑ ባእታታት ኣብ ጣልያን ይፍተኑ ኣለው ።
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
ትሑት ናይ ሞለኪዩላዊ ክብደት ዘለዎ ሄፓሪን ብብዝሒ ሕሙማት ንምሕካም ይጥቅም፡ ብዚ ምኽንያት ከኣ ናይ ጣልያን ሕክምና ኤጀንሲ ናይ ኣጠቃቕማኡ መምርሒታት ንከሐትም ተገዲዱ።
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
ኣብ 300 ሕሙማት ዝተገብረ ናይ ብዙሕ ማእኸል መፅናዕቲ ናይ ኢኖክሳፓሪን ሶድየም ከም መከላኸልን ከም መድሃኒት መጠን ጥቕሚ ንኽፅናዕ ኣብ ጣልያን ኣብ ሚያዝያ 14 ተኣዊጁ።
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
SARS-CoV-2 ቫይረስ ስለዝኾነ፡ ብዙሕ ስነፍልጠታዊ ኣድህቦ ኣብ ቅድሚ ዝርግሐ MERS፡SARS ከምኡ’ውን ናይ ምዕራብ ናይል ቫይረስ ማዕቢሎም ተቐባልነት ንዝረኸቡ ጸረ-ቫይረስ መድሃኒታት ዳግማይ ኣብ ዕላማ ኣብ ምእታው ክግበር ጸኒሑ።
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
ሪባቪሪን: ሪባቪሪን ከም መድሃኒት COVID-19 ኮይኑ ንኽሰርሕ ናይ ቻይና 7ይ ሕታም መምርሒ ይመክር።
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umifenovir(ኡሚፈኖቪር): umifenovir(ኡሚፈኖቪር) ብናይ ቻይና መበል 7ይ ሕታም መሰረት ንኮቪድ-19 መሐከሚ ኣብ ጥቕሚ ክውዕል ተመኺሩ ነይሩ
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
ገለ ጸረ-ረኽሲታት ከም ንኮቪድ-19 መድሓኒት ኮይኖም ክቐርቡ ይኽእሉ እዮም ተባሂሎም ዝተፈለዩ ኣለዉ:
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Tocilizumab(ቶሲሊዙማብ) (ጸረ-IL-6 ተቐባሊ): ኣብ ቻይና ፈቓድ ተዋሂብዎ።
Also trials in Italy and China. and see Tocilizumab#COVID-19.
ከምኡ’ውን ፈተነታት ኣብ ጣልያንን ቻይናንን ቶሲሊዙማብ# COVID-19 ን ርአ።
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
ኣብ እዋን ጥንሲ ዝረኣዩ ኩነታት ከም ሕማም ሽኮር፣ ናይ ልቢ ድኻም፣ናይ ደም ድፍኢት ወይ ድማ ናይ ደም ምርጋእ ልክዕ ከም ኻልኦት ውልቀሰባት ንነፍሰ ጾር እዉን ተወሳኺ ሓደጋ ከምፅእ ከምዝኽእል ንፁር ኣይኮነን። በቲ ዘሎ ዉሑድ መረዳእታ ኣብ እዋን ሳልሳይ ምዕራፍ ጥንሲ ካብ ኣደ ናብ ዕሸል ከምዘይሓልፍ ወይድማ ሓልሓሊፉ ጥራሕ ከምዘጋጥም ይግመት።
There is no data yet on early pregnancy.
ን ኣብ ግዜ መጀመርታ ጥንሲ ዝምልከት ዝኾነ ሓበሬታ ክሳብ ሕጂ የለን።
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
COVID-19 ረኽሲ ኣብ እዋን ጥንሲ ዘምጽኦ ሕማም ብንፁር ንምፍላጥ እኹል መረዳእታ የለን።
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
ካብ ኒውዮርክ 43 ደቂ-ኣንስትዮ ብናይ ኮቪድ-19 መርመራ ናይ ኣኣዎንታ ውጽኢት ዝተረኽበን ምስ ጥንሲ ዘይብለን ተመሳሳልነት ኣርእየን ።86% ፍኹስ ዝበለ ፡ 9.3% ክብድ ዝበለ ከምኡ’ውን 4.7% ኣዛዩ ጽኑዕ ሕማም ኣርእየን ።
Fetal distress was reported in two.
ናይ ዕሸል ረበሻ/ጭንቀት ኣብ ክልተ ተዘጊቡ።
None of the women developed severe COVID-19 pneumonia or died.
ካብተን ደቂ ኣንስትዮ ዋላ ሓንቲ 'ውን ፅዑቕ ናይ COVID-19 ኒሞንያ ዘማዕበለት ውይድማ ዝሞተት የላን።
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
ኩሎም ብጥዕንኦም ዝተወለዱ ጥንሲታት እዮም ኔሮም ከቢድ ናይ ኒዮናታል ኣስፋይሽያ እውን ኣየጋጠመን።
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
ናይ ጸባ ጡብ ኣደ፡ ኣምኒዮቲክ ፈሳሲ፡ ናይ ዕትብቲ ደም ከምኡ’ውን ናይ ናጽላ ናይ ጎሮሮ ብመሓሰስያ ዝተወስዱ ናሙና ንህላወ SARS-CoV-2 ተፈቲኖም ኩሎም ኣሉታዊ ውጽኢት ኣርእዮም ።ኣብ ካልእ ኣብ 15 ጥኑሳት ዝተኻየደ መጽናዕቲ ድማ መብዛሕትኦም ሕሙማት ረስንን ሰዓልን ከለዎም ንናይ ላብራቶሪ መርመራታት ድማ ኣብ 12 ሕሙማት ሊምፎሳይቶፔንያ ከምዘለዎም ኣርእዩ ።
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
ናይ’ዞም ሕሙማት ውጽኢት ኮምፕዩትድ ቶሞግራፊ ምስ ዝቐደሙ ጸብጻባት ናይ ጥኑሳት ዘይኮና ሕሙማት ተቓዳዊ እዩ ።
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
ድሕሪ ሕርሲ ኣብ ክትትል ዝተረኸቡ ናይ ምስሊ መረዳእታታት ዝኾነ ዓይነት ኒሞንያ ምዕባለ ኣየርኣዩን። ናይ ሚድያ ፀብፃባት ክምዘመላኽቱዎ ካብ 100 ንላዕሊ ዝኾና COVID-19 ዘለወን ደቂ ኣንስትዮ ሓሪሰን ክኾና ይኽእላ፣ ኣብ ወርሒ ማርች፣ 2020 ድማ ዝኾነ ዓይነት ናይ ናፅላ ሞት ኣይተፀብፅበን።
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
መምርሒኦም ድማ ዝኾነት ብ COVID-19 ተለኺፋ ኣብ ሆስፒታል ዝኣተወት ጥንሲ ዝሓዘት ሰብ ካብ ሆስፒታል ኣብ ዝተሰናበተትሉ ግዜ ብውሑዱ ን10 መዓልታት ትሑት-ሞለክዩላዊ ክብደት ዘለዎ ሄፓሪን ከም ቅድመ-መከላኸሊ ክውሰድ ይመክር።
There are no data yet concerning the implications of COVID-19 infections for labour.
ምሕማም ብኮቪድ-19 ምስ ሕርሲ ምትእስሳር ከምዘለዎ ዝገልጽ ሓበሬታ ክሳብ ሕጂ የለን ።
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
ካብCOVID-19 ዘለዋ ኣደ ዝተወልደት ሓንቲ ህጻን ክልተ ሰዓታት ድሕሪ ምውላዳ፡ ኣብታ ህጻን ልዑል ደረጃ IgM ብምጽንሑ፡ ኣብ ውሽጢ ማህጸን ከምዝተለኽፈትን ከምኡውን ኣብ ገለ ኩነታት ቀጥታዊ ምትሕልላፍ ናይ ምህላው ተኽእሎ ከም ዘሎ የርእይ።
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
ን 6 ዝተረጋገፀ ናይ COVID-19 ዘለውን ኣደታት ዘጠቓለለ ንእሽተይ መጽናዕቲ ክምዘርኣዮ ኣብቶም ዝተወለዱ ናፅላታት ጉሮሮ ይኹን ኣብ ዘውጹዎም ፍሳሳት ዝኾነ ዓይነት ናይ SARS-COV-19 ምልክት ኣይትርኣየን ይኹን ደኣምበር ኣብ ደሞም ን IgM ሓዊሱ ኣብ ክልተ ናጽላታት ኣብ እዋን ኒዮናታል ብርኪ ህላወ ፀረ ባዕዳዊ ባእታ ተረጋጊፁ እቱ።
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
መብዛሕትኡ ግዜ ካብ ኣደ ናብ ዕሸል ኣይመሓላለፍን እዩ ።ስለ’ዚ ንምሕላፍ እቲ ቫይረስ ብ መዳሕንቲ ወይ ኣብ’ቲ መጽናዕቲ መዳሕንቲ ናይ’ተን ኣዴታት ተጎዲኡ ወይ ዘይንቡር እንተኾይኑ ንምፍላጥ ቀጻሊ መጽናዕቲ የድልይ እዩ።
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
COVID-19 ምስ SARS-CoV ምስስል ዘለዎ ብምዃኑ፣ ኣብ ጽንሲ እውን ተመሳሳሊ እዩ ዝኽውን።
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
ኣርባዕተ ካብ ሸውዓተ ኣብ ቀዳማይ እብረ ሰለስተ ወርሒ ጥንሲ ከይድወን፡ ክልተ ካብ ሓሙሽተ ኣብ ካልኣይ እብረ ሰለስተ ወርሒ ናይ ናጽላ ዕቤት ምዕጋት ኣጋጢምወን ከምኡ’ውን ኣርባዕተ ካብ ሓሙሽተ ቅድሚ ግዜ ሓሪሰን ።
None of the newborns were infected with SARS-CoV.
ካብቶም ሓደሽቲ ዝተወለዱ ህፃውንቲ SARS-CoV ዝሓዞ የለን።
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
ኣብ ሱዑዲ ዓረብ ዓሰርተ ናይ MERS- CoV ረኽሲ ኣመልኪቱ ዝወፅአ ፀብፃብ ክመዘርእዮ እቲ ናይ ክሊኒካዊ ኣቀራርባ ካብ ትሑት ናብ ኣዝዩ ፅዑቕ ረኽሲ ክፍላለ ዝኽእል እዩ።
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
መብዛሕቲኡ ግዜ እቲ ዉፅኢት ፅቡቕ ዋላ እንተነበረ ናይ ህፃዉንቲ ናይ ሞት መጠን ግን 27% እዩ ኔሩ። COVID-19 ንኣዴታትን ህፃዉንትን ካብ SARSን MERSን ፍልይ ብዝበለ መልክዕ ሓደገኛ ከምዘይኮነ ይሕበር። ዋላ እኳ ተኾነ ግን ድሕሪ ናይ 28 ሰሙን ጥንሲ ኣብዘይግዜ ምዉላድ ከምፅእ ይኽእል እዩ።
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
ወድብ ጥዕና ዓለም ን ናይ ኣሜሪካ ማእኸል ቀፅፅር ሕማማን ምክልኻልን ጥንሲ ዘለወን ደቂ ኣንስትዮ ናብ እቲ ረኽሲ ዘልወን ተጋላፅነት ንምቕናስ ክም 'ቲ ኣጠቓላሊ ማሕበረስብ ዝገብሮ ክጋብራ ኣለውን ክም ኣብ ጊዜ ምስዓል ምሽፋን፣ ምስ ሕሙማት ሰባት ካብ ምትንኻፍ ምዕቃብ ን ኣኢዳው ድማ ብ ማይን ብ ሳሙናን ውይድማ ብ ሳኒታይዘር ምፅራይን።
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
ኣብ ሻንጋይ ኣብ ዝተፈላለየ ናይ ጥንሲ ግዘ ዘለዋ ጥኑሳት ዝተኻየደ መጸናዕቲ ከምዘርአዮ ንናይ ጥዕና ሓበሬታን ኣገልግሎትን ልዑል ዝኾነ ናይ ኦንላይን ኣቕርቦት ከምዘድልየን ሓቢሩ።
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
ናይ መጀመሪያ ቆልዓኦም ኣብ ምጸባይ ዝነበሩ ሰባት ካብ እቶም ኣብ ሕሉፍ ዝወለዱ፣ ብ ኢንተርኔት ምኽሪ ኪከታትሉ ብዝበለጸ ፍቃድኛታት ኔሮም። RCOGን RCM እቶም ብኣካል ዝግበሩ ቆጾሮታት ናይ COVID-19 ምልክት ካብ ዝተር ኣየሉ ግዘ ጀሚሩ ብ7 መዓልታት ፍልልይ ውይ ካልእ ሰብ ኣብ ገዛ ምልክት እንተሃልዩዎ 14 መዓልታት ክኸውን ይመኽሩ።
Fever subsequently developed in three asymptomatic patients.
ኣብ ሰለስተ ምልክት ዘየርእዩ ሕሙማት ረስኒ ቀስ ኢሉ ማዕቢሉ።
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
ኣብ መጀመርያ ኣሉታዊ መርመራ ዝነበራ ሓንቲ ተሓካሚት ድሕሪ ሕርሲ ምልክታት ከተርእይ ከምዝጀመረትን፡ እቲ ፋልማይ ኣሉታዊ መርመራ ካብዝግበር ድሕሪ ሰለስተ መዓልታት ኣወንታዊ ውጽኢት ከምዝተረኽበ ተረጋጊጹ።
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
ብሰንኪ ምህላው ምልክታት ዘይብሎም ብዙሕ ቁጽሪ ሕሙማት፡ ረኽሲ ንምንካይን PPE ንምምዳብን ሓፈሻዊ ምምማይ ናይ ጥኑሳት ሕሙማት ክግበር ከም ዘለዎ ነቲ መመመዪ ዘካይዱ ሓካይም ይመኽሩ።
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
ብኮቪድ-19 ዝተጠርጠሩ ወይ ዝተረጋገጹ ሰባት ቀጻላይ ኤሌክትሮኒክ ናይ ህጻናት ክትትል ክግበረሎም ኣለዎ።
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
ብCOVID-19 ዝተጥቕዓ ወይድማ ዝተጠርጠራ ኣዴታት እቲ ቫይረስ ኣብ ሰገራ ክርከብ ስለዝኽእል ኣብ ናይ መሐምበሲ ባስካ ክወልዳ ኣይምከርን።
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
ኣብ UK፣ ዕላዊ መግለጺታት ቅድመ ጥንቃቓዊ ናይ ኣደን ሓድሽ ጥዕንኡ ዝተሓለወ ዕሸልን ምፍላይ ብቐሊሉ ክርአ ዘይብሉ ነገር ከምዝኾነን ድሕሪ ምውላዱ ናይ ኒዮ ናታል ክንክን ዘየድልዮ እንተኾይኑ ምስ ኣዲኡ ክጸንሕ ክግበር ከምዘለዎ ይገልጹ።ናይ ቻይና ስነ-ጽሑፍት ዝተለኸፋ ኣደታት ካብ ደቀን ን 14 መዓልቲታት ክፍለያ ይመኽሩ።
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
ኣብ ሕቡራት መንግስታት ኣሜሪካ ሓደሽቲ ውልዶታትትን ኣዴታትን ንምትሕልላፍ መሰረት ዝገበሩ ጥንቃቐታት ክሳብ ዝቋረጹ ብግዚያውነት ክፍለዩን እዚ ዘይከኣል ምስ ዝኸውን ሓድሽ ውልዶ ካብ ኣደ 2 ሜትር ርሒቑ ክጸንሕ ከምዘለዎ ዝምዕድ ምኽሪ ኣሎ።
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
b'COVID-19 ክትትል ዝርግሐ ናይ ሕማም ኮሮናቫይረስ ዝርግሐ ብምክትታል፡ ናይ እቲ ሕማም ናይ ምዕባለ ኣካይዳት ምስራሕ ዘጠቓልል እዩ።
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
ዓለማዊ ውድብ ጥዕና ንንቑሕ ክትትል ምስ ኩነት ንምርካብ ኣድህቦ ፡ ምምርማር ከምኡ’ውን ምምሕልላፍ ዘጋጥመሎም ርክባት ምጽናዕ ይመክር።
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
ናይ COVID-19 ክትትል ናይ እቲ ሕማም ክስተታት ምቁፅፃር፣ ሓደሽቲ ጉዳያት ለበዳ ብቑልጡፍ ምፍላይ ከምኡ ድማ እዞም መረዳእታታት ብምጥቃም ናይ ስነ-ሕማም ለበዳዊ መረዳእታታት ንሓደጋ ግምገማን ንሕማም ድልዉነትን ከበርክት ይግባእ።
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
ምልክታዊ ክትትል ኣብ ናይ ውልቀ ሰብ ምልክታት ናይ COVID-19 ተመርኲሶም ይትግበሩ።
As of March 2020, the WHO recommends the following case definitions:
ካብ ማርች 2020 ጀሚሩ፣ WHO ነዞም ዝስዕቡ ናይ ጉዳያት ለበዳ ትርጉማት ይመክር:
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
ክኾን ዝኽእል ጉዳይ ለበዳ : "ንናይ ኮቪድ-19 ቫይረስ እንትምርመር ዝተጠርጠረ ጉዳይ ለበዳ መጠቓለሊ ሓሳብ ኣይህብን" ወይ "ዝተጠርጠረ ጉዳይ ለበዳ ግን ብዝኾነ ምኽንያት ምርመራ ክካየደሉ ዘይኽእል እንተኾይኑ"።
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
ዝተረጋገፀ ጉዳይ ለበዳ፡ ‘’ሓደ ሰብ ክሊኒካዊ ምልክት ይሃልዎ ኣይሃለዎ ብቤተ ፈተነ ዝተረጋገፀ ናይ COVID-19 ረኽሲ ምሃላው’’
Direct physical contact with a probable or confirmed case;
ቀጥታዊ ናይ ኣካል ርክብ ምስ ዝተረጋገጸ ወይ ተኽእሎ ዘለዎ ኩነት፡
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
ብዘይ ምንም ናይ ዉልቀ መከላኸሊ ክዳን COVID-19 ከምዘለዎም ዝተረጋገፀ ሕሙማት ወይከዓ ዝተጠርጠሩ ሰባት ዝግበር ቀጥታዊ ክንክን፡
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
ግምገማታት ከባብያዊ ሓደጋ ብዘመልክትዎ ካልኦት ኩነታት”። ዝተጠርጠሩ ከምኡ’ውን ኮቪድ-19 ከምዘለዎም ተረጋገጹ ግዳያት ኣብ ውሽጢ 48 ሰዓታት ክሕበር/ክምዝገብ ከምዘለዎ WHO ይመክር።
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
ብዝተኽኣለ መጠን ሃገራት ሕድሕድ ኬዝ ፅብፃብ ከቕርባ ኣለወን ይኹን ደኣ'ምበር ናይ ምንጭታት ሕፅረት ኣብዝህለወሉ ጥቕሉል ናይ ሰሙናዊ ፀብፃብ እኹል እዩ።
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
ገለ ትካላት ንናይ ሲንድረም ሓለዋታት crowdsourced መተግበሪታት ፈጢሮም ኣለዉ፣ ናይ ኮቪድ-19 ምልክታት በዝሒ ኣብ ዘለዉዎ ናይ መጽናዕቲ ካርታ ንምሕጋዝ ሰባት ምልክታቶም ሪፖርት ክገብሩ ይኽእሉ።
Virological surveillance is done by using molecular tests for COVID-19.
ስነ-ቫይረሳዊ ጽኑዕ ክትትል ሞለክዩላዊ መርመራታት COVID-19 ብምጥቃም ይትግበር።
WHO has published resources for laboratories on how to perform testing for COVID-19.
ዓለማዊ ውድብ ጥዕና ን ኣብ ላብራቶሪ ዝግበር ናይ COVID-19 መርመራ ከመይ ከም ዝትግበር ዝገልጽ ደገፍ ኣሕቲሙ ኣሎ ።
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
ኣብ ናይ ኣውሮፓ ሕብረት፣ ብቤተ-ፈተነ ዝተረጋገጹ ናይ ኮቪድ -19 ጉዳያት ለበዳ ምስ ተፈለዩ ኣብ ውሽጢ 24 ሰዓታት ሪፖርት ይግበሩ እዮም።
At least 24 countries have established digital surveillance of their citizens.
እንተንኢሱ 24 ሃገራት ናይ ዜጋታተን ዲጂታል ሓለዋ ኣጣይሸን ኣለዋ።
The digital surveillance technologies include apps, location data and electronic tags.
እቲ ዲጂታዊ ናይ ክትትል ቴክኖሎጂ ንኣፕሊኬሽናትን ቦታ ምምልካትን ከምኡ’ውን ኤለክሮኒካዊ መፈለጥታ ኣለዎም።
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
ማእከል ምክልኻልን ምቁጽጻርን ሕማም ኣሜሪካ ን ናይ መንገዲ ኣየር ሓበሬታ ገያሾ ብምጥቃም ናይ ወልቀሰባት ናይ ጉዕዞ ሓበሬታታት ይከታተል።
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
ኣብ ሆንግ ኮንግ ሰበ-ስልጣን ገያሾ በናጅርን ኣፕሊኬሽንን ንክህልዎም ይጠልቡ ኣለዉ።
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
GPS app ኣብ ደቡብ ኮርያ ኣብ ሰባት ናይ ኩዋረንቲን ሕጊ ምጥሓስ እንተጋጢሙ ካብ ከባቢኦም ንምርካብን ካብ ዝተፈቐደ ቦታ ሓሊፍካ ምንቅስቓስ እንተሃሊዩ ነቲ ተጠቃማይን በዓል ስልጣናትን መልእኽቲ ንምስዳድን ዝጠቅም እዩ።
In Singapore, individuals have to report their locations with photographic proof.
ኣብ ሲንጋፖር፣ ውልቀሰባት ኣበይ ከምዘለዉ ብፎቶግራፍ ዝተደገፈ መረጋገጺ ጌሮም እዮም ሪፖርት ዝገብሩ።
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
ታይላንድ ኣቶም ካልኦት ሃገራት ንዝመፁ ዑደተኛታት ውሸባ ተግባራዊ ንምግባር፣ መተግበሪን SIM ካርድን ኣብ ምጥቃም ትርከብ።
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
ትካላት ሰብኣዊ መሰላት፡ መንግስታት ነዚ ተላባዒ ሕማም ከም ሽፋን ተጠቂሞም ዜጥቅዕ ዲጂታዊ ክትትል ከየተኣታኣታትው ንገለ ካብ’ቶም ስጉምትታት ነቒፎም ኣለዉ ።
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
b'A ናይ COVID-19 ክትባት ኣብ 2019 ንዘጋጠመ ኮሮና ቫይረስ (COVID-19) ዝከላኸል ናይ ስነሓሳብ ክትባት እዩ።
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
ናይ ክሊኒካዊ ፈትነኡ ዝወደአ ዝኾነ ዓይነት ከትባት እኳ እንተዘይ ሃለወ፣ ነዚ ክምዚ ዝበለ ከትባት ንምምዕባል ብዙሓት ፈተነታት ኣብ መስርሕ ይርከቡ።
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
ኣብ ፌብሩዋሪ 2020 መወዳእታታት፣ ናይ ውድብ ጥዕና ዓለም(WHO) ኣብ ውሽጢ 18 ኣዋርሕ ኣንጻር SARS-CoV-2፣ ነቲ ሕማም ዘስዕብ ቫይረስ ዝኸውን ክትባት ክምዕብል እዩ ኢሉ ከምዘይጽበ ሓቢሩ።
Five vaccine candidates were in Phase I safety studies in April.
ኣብ ሚያዝያ ሓሙሽተ ናይ ክታበት ሕጹያት ኣብ መድረኽ I ናይ ድሕነት መስናዕትታት ኔሮም።
COVID-19 was identified in December 2019.
COVID-19 ኣብ ዲሰምበር 2019 እዩ ህላወኡ ተፈሊጡ።
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
ኣብ 2020 ኣብ መላእ ዓለም ዓብዪ ለበዳ ዝተዘርገሐ እንኾን፣ ክትባት ንምምዕባል ድማ ብዝሕ ዝበለ ኢንቨስትመንትን ናይ መጽናዕቲ ንጥፈታት ኣስዒቡ እዩ።
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
ብዙሓት ትካላት ንSARS-CoV-2 ዝኸዉን ዝተሓተሙ ጄኖማት ብምጥቃም ክትባት ንምምዕባል ይሰርሑ ኣለዉ።
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
ኣብ ኣፕሪል ዝተገለጸ፣ ናይ CEPI ትካል ናይ ክትባት ምዕባለ ወሰንቲ ነጥቢታት፣ ፍጥነት፣ ናይ ምምራት ዓቕሚ፣ ብበዝሒ ምርካብ ምኽኣል፣ ከምኡውን ዓለም ለኻዊ ኣቕርቦታት እዮም።
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
ኣብ ሚያዝያ ናይ CEPI ኣይ ተመራመርቲ ስነ-ፍልጠት 10 ዝተፈላለዩ ናይ ቴክኖሎጂ መድረኻት ኣብ መጀመርታ 2020 ኣድማዒ ክትበት ኣንጻር ኮቪድ-19 ንምፍጣር ኣብ ትሕቲ መጽናዕቲን ምዕባለን ከምዝነበሩ ጸብጻብ ሂቦም።
Major platform targets advanced into Phase I safety studies include:
ናብ ናይ ፌዝ I ናይ ደሕንነት መጽናዕቲ ዝዓበዩ ዋና መድረኻት ነዞም ዝስዕቡ ዘጠቓለሉ እዮም:
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
ኒኩሊክ ኣሲድ (DNA and RNA))( ብርኪ I ኣማዕባሊን ናይ ክትባት ሕፁይን)፡ ሞደርና mRNA-1273)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
viral vector(ቫይራል ቬክተር) (ፌዝ I መማዕበሊን ናይ ክትባት ሕጹይን: CanSino Biologics(ካንሲኖ ባዮሎጂክስ), ኣድኖቫይረስ ዓይነት 5 ቬክተር)
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
ብናይ CEPI ሳንቲስትታት ኣብ ኣፕሪል ሪፖርት ከምዝተገበረ፣ 115 ሓፈሻዊ ናይ ክትባት ሕጹያት ኣብ ናይ ምዕባለ ናይ መጀመርያ ደረጃታት ይርከቡ፣ ምስ 78 ዝተረጋገጹ ንጡፋት ፕሮጀክትታት (79፣ Milken Institute ከምዝበሎ)፣ 37 ካልኦት ድማ ኣዊጆም፣ እንተኾነግን ንእሽተይ ህዝባዊ ሓበሬታ ብምጥቃም እዩ (ኣብ ትልሚ ክህልዉ ዝሕሰቡ ወይ ዝተነደፉ)።
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
ደረጃ I-II ፈተነ ካብ ኩሉ ንላዕሊ ድሕንነት፣ኢምኖጀነሲቲ ምርመራ፣ዘይስሩዕ ኮይኑ ናይ ፕላሴቦ ቁፅፅር ዘለዎ ከምኡ እውን ኣብ ብዙሕ ቦታታት ዝካየድ ኮይኑ ትኽክለኛን ዉፅኢታዉነትን ናይ መድሓኒት መጠን እዉን ዝዉስን እዩ።
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
ናይ ፌዝ III ፈተነታት ዝበዝሑ ተሳተፍቲን መምዘኒ ጉጅለ ዘለዎምን ከምኡ’ውን ንምክልኻል ሕማም ናይ ክታበት ኣድማዕነት ፈተነታት ምስ ምቁጽጻር ኣብ ተደላዩ መጠን መድሃኒት ዝመጽኡ ኣሉታዊ ሳዕቤናት የጠቓልል።
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
ካብ እቶም 79 ኣብ ንጡፍ ምዕባለ ዘለዉ ናይ ክታበት ሕጹያት( April 2020 መጀመርታ ጀሚሩ ዝተረጋገጹ)፡ 74 ኣብ ናይ ወዲ-ሰብ ፈተነ ደረጃ ኣይነበሩን (ሕጂ'ውን ኣብ ቅድመ-ክሊኒካዊ ምርምር እዮም ዘለዉ)።
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
ኣብ ከባቢ ጃንዋሪ 24፣ 2020 ኣብ ኣውስትራሊያ፣ ናይ ኩዊንስ ላንድ ዩኒቨርስቲ ናይ ሞለኪዩላዊ ክላምፕ ን ናይ ቫይርስ ፕሮቲን ብምቕያር ናይ ሰብነት ናይ ሕማም ምክልኻል ተኽእሎ ክነቓቕሕ ዝኽእል ክትባት ዓቕሚ ኣብ ምምርማር ከምዘልው ሓቢሮም ።
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
ኣብ ከባቢ ጃንዋሪ 24፣ 2020 ኣብ ካናዳ ኣብ ሳስካቻውን ዩኒቨርሲቲ ዝርከብ ዓለምለኻዊ ናይ ክትባት ማእኸል(VIDO-InterVac) ኣብ 2021 ፈተነ ዝግበረሉ ክትባት ስራሕ ክምዝ ጀመሩ ኣፍሊጦም።
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
ክትባት ናይ ምምዕባል ፕሮጀክትታት ጃንዋሪ 26፣ 2020 ኣብ ናይ ቻይና ማእኸል ሕማም ቁፅፅርን ምክልኻልን ኣብ ሆንግ ኮንግ ዩኒቨርሲቲ ድማ ኣብ ጃንዋሪ 28 ተጋዊሖም ኣለዉ።
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
ኣብ ከባቢ ጃንዋሪ 29, 2020፡ ጃንሰን ፋርማሰውቲካል ካምፓኒታት ብ መሪሕነት ሃነከ ሽዊተሜከር ንምምዕባል ክታበት ስራሕ ከም ዝጀመሩ ኣፍሊጦም።
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
ጃንሰን ምስ ቫክሳርት ዝተብሃለ ናይ ባዮቴክኖሎጂ መሻርኽቱ ብምትሕብባር ብኣፍ ዝዉሰድ ክትባት የማዕብል ኣሎ።
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
ኣብ መጋቢት 18 2020፡ ኢመርጀንት ባዮ_ሶልዩሽንስ ምስ ቫክሳርት ብምዃን ነቲ ክታበት ንኸማዕብሉ ኣዊጆም ።
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
ኣብ ፌብሩዋሪ 8፣ 2020 ኣብ ሮማኒያ ዝርከብ ና ኦንኮገን ላብራቶሪ ኣብ ምስ ን ካንሰር ኣብ ጥቕሚ ዘወዓለ ኒዮኣንቲጅን ክትባት ሕክምና ዝመሳሰል ናይ ክትባት ቴክኖሎጂ ንድፊ ኣመልኪቱ ናይ ፅናዓት ወረቐት ኣሕቲሞም ኣለው።
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
ኣብ ማርች 25 ፣ናይ ምርምር ትካል ዋና ሓላፊ ናይ ክታበት ምስራሕ ከምዝወድኡን ፈተነታት ኣብ ምጅማር ከምዘለዉ ኣፍሊጦም።
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
ኣብ 27 ፌብሩዋሪ 2020፣ ናይ Generex መሓዛ ትካል, NuGenerex Immuno-Oncology፣ ናይ Ii-Key(ሊ-ኪይ) ፔፕታይድ ክትባት ኣንጻር ኮቪድ-19 ንምፍጣር ናይ ክትባት ፕሮጀክት ይጅምሩ ምህላዎም ኣዊጆም።
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
ኣብ ‘’ዉሽጢ 90 መዓልትታት’’ ኣብ ሰብ ክፍተን ዝኽእል ናይ ክትባት ሕፁይ ንምምዕባል ደልዮም።
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
ኣብ 5 ማርች 2020፣ ናይ Washington University (ዋሽንግተን ዩኒቨርሲቲ) ኣብ St. Louis(ሴንት ሉዊስ) ክትባት ናይ ምምዕባል ፕሮጀክት ኣዊጆም።
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
ኣብ 5 ማርች 2020፣ United States Army Medical Research and Materiel Command at Fort Detrick ን ናይ ኣብ ሲልቨር ስፕሪንግ ዘሎ ናይ Walter Reed Army Institute of Research፣ ክልቲኦም ኣብ ምዕራባዊ ሜሪላንድ ዝርከቡ ኮይኖም፣ ክትባት ኣብ ምምዕባል ይሰረሑ ምህላዎም ድማ ኣዊጆም።